MaxCyte, Inc. reiterated earnings guidance for the year 2024. Management is reiterating 2024 revenue guidance for core business revenue and SPL Program-related revenue. Management expects full year 2024 core business revenue to be flat to 5% growth compared to 2023, and SPL Program-related revenue is expected to be approximately $3 million.

Outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR?s CASGEVYTM and reflects a difficult year-over-year comparison from a client milestone recognized in 2023 that was initially expected in 2024.